Fosravuconazole

Fosravuconazole
Clinical data
Other names	BMS-379224; BFE-1224; E-1224
Identifiers
	IUPAC name [(2R,3R)-3-[4-(4-Cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate;
CAS Number	351227-64-0;
PubChem CID	9807507;
UNII	L4Q6O5430L;
CompTox Dashboard (EPA)	DTXSID70188627 ;
Chemical and physical data
Formula	C23H20F2N5O5PS
Molar mass	547.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)OCOP(=O)(O)O;

Fosravuconazole (trade name Nailin) is a triazole antifungal agent.[1][2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail.[3] It is a prodrug that is converted into ravuconazole.[1]

The Drugs for Neglected Diseases Initiative is studying fosravuconazole as a potential treatment for eumycetoma.[1][4]

References

Yamaguchi, Hideyo (2016). "Potential of Ravuconazole and its Prodrugs as the New Oral Therapeutics for Onychomycosis". Medical Mycology Journal. 57 (4): E93–E110. doi:10.3314/mmj.16-00006. PMID 27904057.
"Fosravuconazole - Seren Pharmaceuticals". Adis Insight.
"Oral Antifungal Agent Nailin Capsules 100 mg Approved in Japan" (Press release). Eisai. January 19, 2018.
"Fosravuconazole". Drugs for Neglected Diseases Initiative.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.